ImmunityBio: ANKTIVA's Commercial Momentum Supports A Buy

ImmunityBio offers a best-in-class, approved immunotherapy, ANKTIVA, driving rapid revenue growth and significant market share in NMIBC. IBRX’s pipeline is robust, with multiple Phase 1-3 trials targeting NSCLC, glioblastoma, HIV, and other high-value indications, supporting long-term upside. The recent 40% pullback from 52-week highs creates an attractive entry point, with strong balance sheet support and no immediate financial risks. ANKTIVA’s superior efficacy, expanding global approvals, and potential label expansion underpin a compelling risk-reward profile despite regulatory and expansion risks.

ImmunityBio ( IBRX ) is a mid-sized biotech currently valued at around $7.745 billion, with an approved drug for BCG Unresponsive NMIBC Carcinoma In-Situ & Papillary that is best-in-class and driving insanely rapid revenue growth.